Trial Profile
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors: CHEERS-trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms CHEERS
- 22 Jan 2024 Status changed from active, no longer recruiting to completed.
- 03 Jan 2023 Planned End Date changed from 14 Aug 2022 to 1 Jan 2024.
- 03 Jan 2023 Planned primary completion date changed from 14 Feb 2022 to 1 Jan 2024.